Chimeric antigen receptor (CAR) T-cell therapy has quickly emerged as a highly 
promising treatment for patients with relapsed and refractory multiple myeloma. 
There are numerous candidates under development, each with their unique 
characteristics and points of differentiation. The most recent US Food and Drug 
Administration approval of the first B-cell maturation antigen-targeted CAR-T 
cell therapy on March 26, 2021, has paved a path forward for the eventual 
evaluation of more of these investigational agents undergoing clinical trials. 
Herein, we highlight, from a clinical development perspective, the CAR-T cell 
therapies farthest along in development with updated data from the American 
Society of Hematology 2020 annual meeting. We also discuss potential paths of 
overcoming resistance to these therapies and the future direction for CAR-T cell 
therapeutics in multiple myeloma.